Recent News

Early-Stage Clinical Study of Novel BCMA CAR T-Cell Therapy in Resistant Myeloma

Does Combination Immunotherapy Improve Survival in Metastatic Uveal Melanoma?

Adding Palbociclib to Cetuximab in Platinum-Resistant Head and Neck Cancer

FOLFOXIRI Plus Bevacizumab in Unresectable Coloretcal Cancer: Update From TRIBE2

CLL14 Trial: Paired With Obinutuzumab, Venetoclax Versus Chlorambucil in CLL

Epacadostat With Pembrolizumab in Advanced Melanoma

IMpassion130 Trial: Atezolizumab Plus Nab-paclitaxel in Advanced Triple-Negative Breast Cancer

Novel Monoclonal Antibody Plus Cetuximab Under Study in Head/Neck Cancer

Infliximab Therapy With Tyrosine Kinase Inhibition in CML

Nivolumab for Advanced Renal Cell Carcinoma: 5-Year Survival

Using Immuno-PET to Detect PD-L1 in Renal Cell Carcinoma: Case Report

CD19-Directed Immunotherapy for Relapsed or Refractory CLL

Bempegaldesleukin With Nivolumab Granted Breakthrough Therapy Designation in Melanoma

FDA Approves Rituximab Biosimilar for CLL

FDA Approves Pembrolizumab in PD-L1–Expressing Squamous Cell Carcinoma of the Esophagus

Subcutaneous Versus Intravenous Daratumumab in Resistant Multiple Myeloma

Does Eribulin Mesylate Plus Pembrolizumab Improve Outcomes in Metastatic Breast Cancer?

Checkpoint Inhibitors in Oropharyngeal Cancer: Window-of-Opportunity Trial

Mirvetuximab Soravtansine Plus Bevacizumab in Platinum-Resistant Ovarian Cancer

Intermittent Nivolumab Dosing for Metastatic Renal Cell Carcinoma

First Clinical Immunotherapy Treatment Guidelines for Squamous Cell Carcinoma of the Head and Neck

Updated ELOQUENT Data Support Elotuzumab Combination Regimen in Myeloma

Novel Immunotherapy Combination Active in Metastatic Melanoma

FDA Accepts sBLAs for 6-Week Dosing Schedule of Pembrolizumab for Merkel Cell Carcinoma

FDA Accepts sBLAs for 6-Week Dosing Schedule of Pembrolizumab for Melanoma

Cemiplimab-rwlc Approved for Advanced Cutaneous Squamous Cell Carcinoma in European Union

Is Immunotherapy With Cytoreductive Surgery Feasible in Metastatic Kidney Cancer?

EHA24 Congress: Selinexor With Daratumumab and Dexamethasone in Resistant Myeloma

SOPHIA Trial: Adding Margetuximab or Trastuzumab to Chemotherapy in Breast Cancer

EAGLE Trial: Novel Immunotherapies for Resistant Head/Neck Cancer

Atezolizumab Plus Bevacizumab for Sarcomatoid Metastatic Renal Cell Carcinoma

Addition of Isatuximab to Pomalidomide/Dexamethasone in Multiple Myeloma

ICML 2019: Improved Outcomes With Brentuximab Vedotin in Cutaneous Lymphoma

FDA Approves Bevacizumab Biosimilar in Nonsquamous NSCLC

ICML 2019: Mogamulizumab in Cutaneous T-Cell Lymphoma

FDA Approves Daratumumab Combination for Newly Diagnosed Transplant-Ineligible Patients With Multiple Myeloma